Ronnie Tung‐ping Poon
#143,169
Most Influential Person Now
Ronnie Tung‐ping Poon's AcademicInfluence.com Rankings
Ronnie Tung‐ping Poonphilosophy Degrees
Philosophy
#7573
World Rank
#10807
Historical Rank
Logic
#4623
World Rank
#5939
Historical Rank

Download Badge
Philosophy
Why Is Ronnie Tung‐ping Poon Influential?
(Suggest an Edit or Addition)Ronnie Tung‐ping Poon's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma (2002) (2397)
- Significance of CD90+ cancer stem cells in human liver cancer. (2008) (1173)
- Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma (2010) (1013)
- Long-Term Survival and Pattern of Recurrence After Resection of Small Hepatocellular Carcinoma in Patients With Preserved Liver Function: Implications for a Strategy of Salvage Transplantation (2002) (813)
- Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. (2015) (697)
- Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma (2000) (692)
- Improving Perioperative Outcome Expands the Role of Hepatectomy in Management of Benign and Malignant Hepatobiliary Diseases: Analysis of 1222 Consecutive Patients From a Prospective Database (2004) (667)
- Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. (2013) (649)
- Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. (2015) (639)
- Clinical implications of circulating angiogenic factors in cancer patients. (2001) (600)
- Improving Survival Results After Resection of Hepatocellular Carcinoma: A Prospective Study of 377 Patients Over 10 Years (2001) (580)
- Intrahepatic recurrence after curative resection of hepatocellular carcinoma: long-term results of treatment and prognostic factors. (1999) (558)
- Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma. (2014) (543)
- A subpopulation of CD26+ cancer stem cells with metastatic capacity in human colorectal cancer. (2010) (523)
- Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. (2013) (522)
- Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial. (2014) (513)
- Locoregional Therapies for Hepatocellular Carcinoma: A Critical Review From the Surgeon’s Perspective (2002) (414)
- Twist Overexpression Correlates with Hepatocellular Carcinoma Metastasis through Induction of Epithelial-Mesenchymal Transition (2006) (410)
- Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. (2010) (378)
- Identification of local and circulating cancer stem cells in human liver cancer (2008) (345)
- Continuous Improvement of Survival Outcomes of Resection of Hepatocellular Carcinoma: A 20-Year Experience (2011) (333)
- The microRNA miR-139 suppresses metastasis and progression of hepatocellular carcinoma by down-regulating Rho-kinase 2. (2011) (291)
- Alternatively activated (M2) macrophages promote tumour growth and invasiveness in hepatocellular carcinoma. (2015) (290)
- A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. (2007) (286)
- Tumor microvessel density as a predictor of recurrence after resection of hepatocellular carcinoma: a prospective study. (2002) (281)
- Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial (2014) (250)
- Serum Vascular Endothelial Growth Factor Predicts Venous Invasion in Hepatocellular Carcinoma : A Prospective Study (2001) (246)
- Is Hepatic Resection for Large or Multinodular Hepatocellular Carcinoma Justified? Results From a Multi-Institutional Database (2005) (245)
- Abdominal Drainage After Hepatic Resection Is Contraindicated in Patients With Chronic Liver Diseases (2004) (224)
- External drainage of pancreatic duct with a stent to reduce leakage rate of pancreaticojejunostomy after pancreaticoduodenectomy: a prospective randomized trial. (2008) (223)
- Octamer 4 (Oct4) mediates chemotherapeutic drug resistance in liver cancer cells through a potential Oct4–AKT–ATP‐binding cassette G2 pathway (2010) (216)
- Hepatectomy for hepatocellular carcinoma: Patient selection and postoperative outcome (2004) (212)
- Learning Curve for Radiofrequency Ablation of Liver Tumors: Prospective Analysis of Initial 100 Patients in a Tertiary Institution (2004) (206)
- Quantitative correlation of serum levels and tumor expression of vascular endothelial growth factor in patients with hepatocellular carcinoma. (2003) (203)
- Prospective Evaluation of Selective Defunctioning Stoma for Low Anterior Resection with Total Mesorectal Excision (1999) (199)
- Prevention of pancreatic anastomotic leakage after pancreaticoduodenectomy. (2002) (192)
- Recurrence of Hepatitis B-Related Hepatocellular Carcinoma Is Associated With High Viral Load at the Time of Resection (2008) (182)
- Interleukin-8 serum levels in patients with hepatocellular carcinoma: correlations with clinicopathological features and prognosis. (2003) (182)
- A randomized placebo‐controlled study of long‐acting octreotide for the treatment of advanced hepatocellular carcinoma (2002) (181)
- Risk for hepatocellular carcinoma with respect to hepatitis B virus genotypes B/C, specific mutations of enhancer II/core promoter/precore regions and HBV DNA levels (2007) (180)
- From Molecular Biology to Targeted Therapies for Hepatocellular Carcinoma: The Future Is Now (2007) (179)
- Extended Hepatic Resection for Hepatocellular Carcinoma in Patients with Cirrhosis: Is It Justified? (2002) (177)
- Tissue factor expression correlates with tumor angiogenesis and invasiveness in human hepatocellular carcinoma. (2003) (177)
- Long-term prognosis after resection of hepatocellular carcinoma associated with hepatitis B-related cirrhosis. (2000) (174)
- Difference in Tumor Invasiveness in Cirrhotic Patients With Hepatocellular Carcinoma Fulfilling the Milan Criteria Treated by Resection and Transplantation: Impact on Long-term Survival (2007) (171)
- Vascular Changes in Hepatocellular Carcinoma (2008) (167)
- Transarterial chemoembolization for inoperable hepatocellular carcinoma and postresection intrahepatic recurrence (2000) (164)
- Clinicopathologic features of long-term survivors and disease-free survivors after resection of hepatocellular carcinoma: a study of a prospective cohort. (2001) (158)
- Microvessel density, vascular endothelial growth factor and its receptors Flt-1 and Flk-1/KDR in hepatocellular carcinoma. (2001) (158)
- External Drainage of Pancreatic Duct With a Stent to Reduce Leakage Rate of Pancreaticojejunostomy After Pancreaticoduodenectomy: A Prospective Randomized Trial (2007) (157)
- Phase 2 open‐label study of single‐agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B–endemic Asian population (2009) (155)
- Selection criteria for hepatic resection in patients with large hepatocellular carcinoma larger than 10 cm in diameter. (2002) (153)
- Long-Term Survival Analysis of Pure Laparoscopic Versus Open Hepatectomy for Hepatocellular Carcinoma in Patients With Cirrhosis: A Single-Center Experience (2013) (144)
- Significance of circulating endothelial progenitor cells in hepatocellular carcinoma (2006) (140)
- Macrophage migration inhibitory factor: Roles in regulating tumor cell migration and expression of angiogenic factors in hepatocellular carcinoma (2003) (137)
- Determination of the molecular relationship between multiple tumour nodules in hepatocellular carcinoma differentiates multicentric origin from intrahepatic metastasis (2003) (136)
- Occult hepatitis B infection and HBV replicative activity in patients with cryptogenic cause of hepatocellular carcinoma (2011) (135)
- Suppression of Liver Tumor Growth and Metastasis by Adiponectin in Nude Mice through Inhibition of Tumor Angiogenesis and Downregulation of Rho Kinase/IFN-Inducible Protein 10/Matrix Metalloproteinase 9 Signaling (2010) (135)
- Correlation of serum basic fibroblast growth factor levels with clinicopathologic features and postoperative recurrence in hepatocellular carcinoma. (2001) (132)
- Genomic Profiling of Intrahepatic Cholangiocarcinoma: Refining Prognosis and Identifying Therapeutic Targets (2014) (125)
- High Serum Vascular Endothelial Growth Factor Levels Predict Poor Prognosis after Radiofrequency Ablation of Hepatocellular Carcinoma: Importance of Tumor Biomarker in Ablative Therapies (2007) (122)
- Comparison of early endoscopic ultrasonography and endoscopic retrograde cholangiopancreatography in the management of acute biliary pancreatitis: a prospective randomized study. (2005) (119)
- Ischemia‐reperfusion of small liver remnant promotes liver tumor growth and metastases—Activation of cell invasion and migration pathways (2007) (118)
- High serum levels of vascular endothelial growth factor predict poor response to transarterial chemoembolization in hepatocellular carcinoma: a prospective study. (2004) (116)
- Signal transducers and activators of transcription 5b activation enhances hepatocellular carcinoma aggressiveness through induction of epithelial-mesenchymal transition. (2006) (115)
- High-Intensity Focused Ultrasound for Hepatocellular Carcinoma: A Single-Center Experience (2011) (114)
- Impact of antiviral therapy on the survival of patients after major hepatectomy for hepatitis B virus-related hepatocellular carcinoma. (2011) (114)
- Treatment strategy for recurrent hepatocellular carcinoma: Salvage transplantation, repeated resection, or radiofrequency ablation? (2013) (113)
- Clinicopathological and prognostic significance of serum and tissue Dickkopf‐1 levels in human hepatocellular carcinoma (2011) (113)
- Allograft inflammatory factor-1 (AIF-1) is crucial for the survival and pro-inflammatory activity of macrophages. (2005) (112)
- PIN1 overexpression and β-catenin gene mutations are distinct oncogenic events in human hepatocellular carcinoma (2004) (109)
- An Akt/Hypoxia-Inducible Factor-1α/Platelet-Derived Growth Factor-BB Autocrine Loop Mediates Hypoxia-Induced Chemoresistance in Liver Cancer Cells and Tumorigenic Hepatic Progenitor Cells (2009) (109)
- Circulating Oncometabolite 2-Hydroxyglutarate Is a Potential Surrogate Biomarker in Patients with Isocitrate Dehydrogenase-Mutant Intrahepatic Cholangiocarcinoma (2014) (109)
- Microvascular Invasion Does Not Predict Long-Term Survival in Hepatocellular Carcinoma up to 2 cm: Reappraisal of the Staging System for Solitary Tumors (2013) (108)
- The significance of early alpha-fetoprotein level changes in predicting clinical and survival benefits in advanced hepatocellular carcinoma patients receiving sorafenib. (2011) (107)
- Current techniques of liver transection. (2007) (107)
- Aggressive management of patients with extrahepatic and intrahepatic recurrences of hepatocellular carcinoma by combined resection and locoregional therapy. (2002) (106)
- Over-Expression of miR-106b Promotes Cell Migration and Metastasis in Hepatocellular Carcinoma by Activating Epithelial-Mesenchymal Transition Process (2013) (103)
- Prognosis After Hepatic Resection for Stage IVA Hepatocellular Carcinoma: A Need for Reclassification (2003) (102)
- A prospective longitudinal study of quality of life after resection of hepatocellular carcinoma. (2001) (102)
- Hepatic resection for combined hepatocellular and cholangiocarcinoma. (2003) (100)
- Survival Analysis of Re-resection Versus Radiofrequency Ablation for Intrahepatic Recurrence After Hepatectomy for Hepatocellular Carcinoma (2011) (99)
- Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584. (2005) (98)
- FTY720: A Promising Agent for Treatment of Metastatic Hepatocellular Carcinoma (2005) (97)
- The Enhanced Metastatic Potential of Hepatocellular Carcinoma (HCC) Cells with Sorafenib Resistance (2013) (96)
- Evaluation of the new AJCC/UICC staging system for hepatocellular carcinoma after hepatic resection in Chinese patients. (2003) (96)
- Identification of brain-derived neurotrophic factor as a novel functional protein in hepatocellular carcinoma. (2005) (96)
- Biology of Hepatocellular Carcinoma (2008) (94)
- 1398 BRIVANIB VERSUS PLACEBO IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC) WHO FAILED OR WERE INTOLERANT TO SORAFENIB: RESULTS FROM THE PHASE 3 BRISK-PS STUDY (2012) (92)
- Surgical Outcomes in Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombosis (2014) (91)
- Treatment of advanced hepatocellular carcinoma with tamoxifen and the correlation with expression of hormone receptors: a prospective randomized study (2000) (90)
- Clinical Significance of Thrombospondin 1 Expression in Hepatocellular Carcinoma (2004) (90)
- Tuberculosis of pancreas and peripancreatic lymph nodes in immunocompetent patients: experience from China. (2003) (90)
- Phase III HEAT Study Adding Lyso-Thermosensitive Liposomal Doxorubicin to Radiofrequency Ablation in Patients with Unresectable Hepatocellular Carcinoma Lesions (2017) (87)
- Effects of a novel immunomodulating agent, FTY720, on tumor growth and angiogenesis in hepatocellular carcinoma (2005) (87)
- Pancreaticoduodenectomy with En Bloc Portal Vein Resection for Pancreatic Carcinoma with Suspected Portal Vein Involvement (2004) (87)
- A Garlic Derivative, S-allylcysteine (SAC), Suppresses Proliferation and Metastasis of Hepatocellular Carcinoma (2012) (85)
- A Phase II Study of the Efficacy and Safety of the Combination Therapy of the MEK Inhibitor Refametinib (BAY 86-9766) Plus Sorafenib for Asian Patients with Unresectable Hepatocellular Carcinoma (2014) (85)
- Choledochal cysts in adults. (2002) (84)
- Quantification of hepatitis B virus covalently closed circular DNA in patients with hepatocellular carcinoma. (2006) (83)
- Sustained disease remission after spontaneous HBeAg seroconversion is associated with reduction in fibrosis progression in chronic hepatitis B Chinese patients (2007) (83)
- A phase 1 dose-escalating study of pegylated recombinant human arginase 1 (Peg-rhArg1) in patients with advanced hepatocellular carcinoma (2012) (83)
- Clinical Significance of Angiogenesis in Gastrointestinal Cancers: A Target for Novel Prognostic and Therapeutic Approaches (2003) (82)
- Surgery for Intermediate and Advanced Hepatocellular Carcinoma: A Consensus Report from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014) (2016) (81)
- TSC1/2 mutations define a molecular subset of HCC with aggressive behaviour and treatment implication (2016) (81)
- Phase I Dose-Finding Study of Pazopanib in Hepatocellular Carcinoma: Evaluation of Early Efficacy, Pharmacokinetics, and Pharmacodynamics (2011) (80)
- Management of advanced hepatocellular carcinoma in the era of targeted therapy (2009) (79)
- Effectiveness of radiofrequency ablation for hepatocellular carcinomas larger than 3 cm in diameter. (2004) (78)
- Tumor cyclooxygenase-2 levels correlate with tumor invasiveness in human hepatocellular carcinoma. (2005) (77)
- Hepatocellular carcinoma in the elderly: results of surgical and nonsurgical management (1999) (77)
- Can positron emission tomography with the dual tracers [11C]acetate and [18F]fludeoxyglucose predict microvascular invasion in hepatocellular carcinoma? (2011) (76)
- Evaluation of the seventh edition of the American Joint Committee on Cancer tumour-node-metastasis (TNM) staging system for patients undergoing curative resection of hepatocellular carcinoma: implications for the development of a refined staging system. (2013) (75)
- Changing Paradigm in the Management of Hepatocellular Carcinoma Improves the Survival Benefit of Early Detection by Screening (2008) (74)
- Notch1‐Snail1‐E‐cadherin pathway in metastatic hepatocellular carcinoma (2012) (74)
- Gold(III) compound is a novel chemocytotoxic agent for hepatocellular carcinoma (2006) (74)
- Management of carcinoma of the gallbladder: A single‐institution experience in 16 years (2008) (73)
- Radiofrequency ablation for malignant liver tumor. (2005) (73)
- Liver Cancer Working Group report. (2010) (72)
- Inhibition of mTOR enhances chemosensitivity in hepatocellular carcinoma. (2009) (71)
- Randomized, open‐label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma (2016) (71)
- Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma. (2013) (70)
- Re‐evaluating transarterial chemoembolization for the treatment of Hepatocellular Carcinoma: Consensus recommendations and review by an International Expert Panel (2014) (70)
- Evolution of systemic therapy of advanced hepatocellular carcinoma. (2008) (69)
- Brain-Derived Neurotrophic Factor Promotes Tumorigenesis via Induction of Neovascularization: Implication in Hepatocellular Carcinoma (2011) (67)
- Liver resection using a saline-linked radiofrequency dissecting sealer for transection of the liver. (2005) (67)
- Overexpression of matrix metalloproteinase-12 (MMP-12) correlates with poor prognosis of hepatocellular carcinoma. (2011) (66)
- Genome-Wide Association Study of Hepatocellular Carcinoma in Southern Chinese Patients with Chronic Hepatitis B Virus Infection (2011) (65)
- Oncoproteomics of hepatocellular carcinoma: from cancer markers' discovery to functional pathways (2007) (65)
- The use of single‐agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child‐Pugh B liver cirrhosis (2012) (65)
- ALPPS Versus Portal Vein Embolization for Hepatitis-related Hepatocellular Carcinoma (2019) (64)
- A new prognostic score system in patients with advanced hepatocellular carcinoma not amendable to locoregional therapy (2008) (64)
- Regulation of Angiogenesis by Id-1 through Hypoxia-Inducible Factor-1α–Mediated Vascular Endothelial Growth Factor Up-regulation in Hepatocellular Carcinoma (2006) (63)
- Preliminary efficacy, safety, pharmacokinetics, pharmacodynamics and quality of life study of pegylated recombinant human arginase 1 in patients with advanced hepatocellular carcinoma (2015) (63)
- Perioperative and long-term outcome of major hepatic resection for small solitary hepatocellular carcinoma in patients with cirrhosis. (2003) (62)
- Survival analysis of patients with transplantable recurrent hepatocellular carcinoma: implications for salvage liver transplant. (2008) (62)
- Outcome of laparoscopic versus open hepatectomy for colorectal liver metastases (2013) (62)
- The outcomes and safety of single-agent sorafenib in the treatment of elderly patients with advanced hepatocellular carcinoma (HCC). (2011) (61)
- Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study. (2017) (60)
- Inhibition of Stat3 activity by YC-1 enhances chemo-sensitivity in hepatocellular carcinoma (2007) (59)
- Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease (2012) (59)
- STORM: A phase III randomized, double-blind, placebo-controlled trial of adjuvant sorafenib after resection or ablation to prevent recurrence of hepatocellular carcinoma (HCC) (2014) (58)
- Octamer 4 ( Oct 4 ) Mediates Chemotherapeutic Drug Resistance in Liver Cancer Cells Through a Potential Oct 4 – AKT – ATP-Binding Cassette G 2 Pathway (2010) (58)
- Comparison of percutaneous and surgical approaches for radiofrequency ablation of small and medium hepatocellular carcinoma. (2007) (58)
- Inflammatory Cecal Masses in Patients Presenting with Appendicitis (1999) (57)
- Porcine liver: morphologic characteristics and cell viability at experimental radiofrequency ablation with internally cooled electrodes. (2005) (57)
- Clinicopathological and prognostic implications of endoglin (CD105) expression in hepatocellular carcinoma and its adjacent non-tumorous liver. (2005) (57)
- Assessment of hepatic reserve for indication of hepatic resection: how I do it. (2005) (56)
- Comparison of Systemic Responses of Radiofrequency Ablation, Cryotherapy, and Surgical Resection in a Porcine Liver Model (2004) (55)
- Outcomes of Patients with Hepatocellular Carcinoma Presenting with Variceal Bleeding (2004) (51)
- Hepatic angiomyolipoma. (2003) (51)
- Hepatic resection for bilobar hepatocellular carcinoma: is it justified? (2003) (51)
- Rac Activation Is Associated with Hepatocellular Carcinoma Metastasis by Up-regulation of Vascular Endothelial Growth Factor Expression (2006) (50)
- Significance of the Rac signaling pathway in HCC cell motility: implications for a new therapeutic target. (2005) (50)
- High-intensity focused ultrasound ablation: an effective bridging therapy for hepatocellular carcinoma patients. (2013) (49)
- Over-expression of Id-1 induces cell proliferation in hepatocellular carcinoma through inactivation of p16INK4a/RB pathway. (2003) (49)
- Cancer stem cell as a potential therapeutic target in hepatocellular carcinoma. (2012) (49)
- Suppression of tumorigenesis and metastasis of hepatocellular carcinoma by shRNA interference targeting on homeoprotein Six1 (2010) (48)
- Is primary resection and salvage transplantation for hepatocellular carcinoma a reasonable strategy? (2004) (48)
- Recent Advances in the Prevention of Hepatocellular Carcinoma Recurrence (2014) (48)
- Does diabetes mellitus influence the perioperative outcome or long term prognosis after resection of hepatocellular carcinoma? (2002) (47)
- Phase I study of the safety and efficacy of INC280 in patients with advanced MET-dependent solid tumors. (2014) (46)
- Proline-Rich Tyrosine Kinase 2 (Pyk2) Promotes Cell Motility of Hepatocellular Carcinoma through Induction of Epithelial to Mesenchymal Transition (2011) (45)
- Results of percutaneous transhepatic cholecystostomy for high surgical risk patients with acute cholecystitis (2010) (44)
- Hong Kong Consensus Recommendations on the Management of Hepatocellular Carcinoma (2015) (43)
- Phase 1 study of capmatinib in MET‐positive solid tumor patients: Dose escalation and expansion of selected cohorts (2019) (43)
- The outcomes of elderly patients with hepatocellular carcinoma treated with transarterial chemoembolization (2009) (42)
- Feasibility of Laparoscopic Re-resection for Patients with Recurrent Hepatocellular Carcinoma (2014) (42)
- Radiofrequency Ablation for Subcapsular Hepatocellular Carcinoma (2004) (41)
- Differentiating Early and Late Recurrences After Resection of HCC in Cirrhotic Patients: Implications on Surveillance, Prevention, and Treatment Strategies (2009) (41)
- Safety of ALPPS Procedure by the Anterior Approach for Hepatocellular Carcinoma. (2016) (41)
- EVOLVE-1: Phase 3 study of everolimus for advanced HCC that progressed during or after sorafenib. (2014) (40)
- Comparative proteomic analysis of mouse livers from embryo to adult reveals an association with progression of hepatocellular carcinoma (2008) (40)
- Outcome of transarterial chemoembolization in patients with inoperable hepatocellular carcinoma eligible for radiofrequency ablation. (2005) (40)
- Laparoscopic versus open liver resection for elderly patients with malignant liver tumors: A single‐center experience (2014) (40)
- Resection prior to liver transplantation for hepatocellular carcinoma: A strategy of optimizing the role of resection and transplantation in cirrhotic patients with preserved liver function (2004) (39)
- Desensitization of T lymphocyte function by CXCR3 ligands in human hepatocellular carcinoma. (2005) (39)
- Clinical relevance and therapeutic potential of angiopoietin-like protein 4 in hepatocellular carcinoma (2014) (39)
- Chemokine receptors support infiltration of lymphocyte subpopulations in human hepatocellular carcinoma. (2005) (39)
- Liver Intestine-Cadherin (CDH17) Haplotype Is Associated with Increased Risk of Hepatocellular Carcinoma (2006) (38)
- Suppression of hypoxia inducible factor-1α (HIF-1α) by YC-1 is dependent on murine double minute 2 (Mdm2) (2006) (38)
- Pancreaticoduodenectomy with vascular reconstruction for adenocarcinoma of the pancreas with borderline resectability. (2014) (37)
- A Phase I/II Multicenter Study of Single-Agent Foretinib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma (2016) (37)
- Osteopontin Overexpression Induced Tumor Progression and Chemoresistance to Oxaliplatin through Induction of Stem-Like Properties in Human Colorectal Cancer (2015) (36)
- The Role of Proline Rich Tyrosine Kinase 2 (Pyk2) on Cisplatin Resistance in Hepatocellular Carcinoma (2011) (35)
- Post-Operative Plasma Osteopontin Predicts Distant Metastasis in Human Colorectal Cancer (2015) (34)
- Pure Laparoscopic Versus Open Left Lateral Sectionectomy for Hepatocellular Carcinoma: A Single-Center Experience (2015) (34)
- PTK787/ZK22258 attenuates stellate cell activation and hepatic fibrosis in vivo by inhibiting VEGF signaling (2009) (34)
- Use of Liver Stiffness Measurement for Liver Resection Surgery: Correlation with Indocyanine Green Clearance Testing and Post-Operative Outcome (2013) (33)
- Granulin–Epithelin Precursor Renders Hepatocellular Carcinoma Cells Resistant to Natural Killer Cytotoxicity (2014) (33)
- Aberrant Polo-Like Kinase 1-Cdc25A Pathway in Metastatic Hepatocellular Carcinoma (2008) (33)
- Thoracoabdominal approach for right-sided hepatic resection for hepatocellular carcinoma. (2003) (33)
- Biomarkers for predicting future metastasis of human gastrointestinal tumors (2013) (33)
- Antiinflammatory properties of IL‐10 rescue small‐for‐size liver grafts (2007) (32)
- Identification of Transmembrane Protein 98 as a Novel Chemoresistance-Conferring Gene in Hepatocellular Carcinoma (2014) (31)
- Anti-tumor efficacy of a recombinant human arginase in human hepatocellular carcinoma. (2012) (30)
- A phase I/II study of foretinib, an oral multikinase inhibitor targeting MET, RON, AXL, TIE-2, and VEGFR in advanced hepatocellular carcinoma (HCC). (2012) (30)
- The kringle 1 domain of hepatocyte growth factor has antiangiogenic and antitumor cell effects on hepatocellular carcinoma. (2008) (30)
- Impact of preoperative fine-needle aspiration cytologic examination on clinical outcome in patients with hepatocellular carcinoma in a tertiary referral center. (2004) (30)
- Comparable survival in patients with unresectable hepatocellular carcinoma treated by radiofrequency ablation or transarterial chemoembolization. (2006) (30)
- Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Analysis of patients with elevated {alpha}-fetoprotein (AFP) from the randomized phase III REACH study. (2015) (30)
- Platelet activation during tumor development, the potential role of BDNF-TrkB autocrine loop. (2006) (30)
- Suppression of hypoxia inducible factor-1alpha (HIF-1alpha) by YC-1 is dependent on murine double minute 2 (Mdm2). (2006) (29)
- Marked suppression of tumor growth by FTY720 in a rat liver tumor model: the significance of down-regulation of cell survival Akt pathway. (2007) (28)
- Efficacy and Tolerability of Low-Dose Thalidomide as First-Line Systemic Treatment of Patients with Advanced Hepatocellular Carcinoma (2007) (28)
- Recent advances in techniques of liver resection. (2004) (28)
- Survival analysis of high‐intensity focused ultrasound therapy vs. transarterial chemoembolization for unresectable hepatocellular carcinomas (2014) (27)
- Inflammatory pseudotumor of the liver in association with a gastrointestinal stromal tumor: a case report. (2004) (26)
- Integrative biomarker analyses indicate etiological variations in hepatocellular carcinoma. (2016) (26)
- Pancreatic-induced intramural duodenal haematoma. (2008) (26)
- Survival analysis of transarterial radioembolization with yttrium-90 for hepatocellular carcinoma patients with HBV infection. (2014) (26)
- Digestive cancer management in Asia: Position statements: A report on GI Oncology Summit in 2011 (2012) (25)
- Comparison of systemic responses of radiofrequency ablation, cryotherapy and surgical resection in a porcine liver model (2004) (25)
- Safety limit of large-volume hepatic radiofrequency ablation in a rat model. (2006) (25)
- Establishment and characterization of a novel primary hepatocellular carcinoma cell line with metastatic ability in vivo (2014) (25)
- Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study (2018) (25)
- Reduced Expression of Chemokine Receptors on Peripheral Blood Lymphocytes in Patients with Hepatocellular Carcinoma (2004) (25)
- Therapeutic efficacy of Traditional Chinese Medicine 319 recipe on hepatic fibrosis induced by carbon tetrachloride in rats. (2009) (24)
- Decreasing the pancreatic leak rate after pancreaticoduodenectomy. (2008) (24)
- High doses of tyrosine kinase inhibitor PTK787 enhance the efficacy of ischemic hypoxia for the treatment of hepatocellular carcinoma: dual effects on cancer cell and angiogenesis (2006) (24)
- Risk Factors and Post-Resection Independent Predictive Score for the Recurrence of Hepatitis B-Related Hepatocellular Carcinoma (2016) (24)
- LBA16RAMUCIRUMAB (RAM) AS SECOND-LINE TREATMENT IN PATIENTS (PTS) WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC) FOLLOWING FIRST-LINE THERAPY WITH SORAFENIB: RESULTS FROM THE RANDOMIZED PHASE III REACH STUDY (2014) (23)
- Portal vein thrombosis after radiofrequency ablation for recurrent hepatocellular carcinoma. (2003) (22)
- A phase I study of pazopanib in patients with advanced hepatocellular carcinoma. (2009) (22)
- The Clinicopathological Significance of miR-133a in Colorectal Cancer (2014) (22)
- Tolerance of radiofrequency ablation by patients of hepatocellular carcinoma. (2009) (22)
- Cardiotrophin‐1 enhances regeneration of cirrhotic liver remnant after hepatectomy through promotion of angiogenesis and cell proliferation (2008) (22)
- A case of laparoscopic hepatectomy for recurrent hepatocellular carcinoma. (2010) (21)
- Trans‐arterial chemo‐embolization is safe and effective for elderly advanced hepatocellular carcinoma patients: results from an international database (2014) (21)
- Deleted in liver cancer 1 isoforms are distinctly expressed in human tissues, functionally different and under differential transcriptional regulation in hepatocellular carcinoma (2010) (21)
- Significance of the serum brain-derived neurotrophic factor and platelets in hepatocellular carcinoma. (2006) (21)
- Phase I study of everolimus in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC). (2011) (20)
- Antisecretory agents for prevention of post-ERCP pancreatitis: rationale for use and clinical results. (2003) (20)
- Randomized phase II trial of intravenous RO5137382/GC33 at 1600 mg every other week and placebo in previously treated patients with unresectable advanced hepatocellular carcinoma (HCC; NCT01507168). (2014) (20)
- Expression of ankyrin repeat and SOCS box containing 4 (ASB4) confers migration and invasion properties of hepatocellular carcinoma cells. (2014) (20)
- Value of live donor liver transplantation experience in major hepatectomy for hepatocellular carcinoma. (2003) (19)
- Disruption of p53-p21/WAF1 cell cycle pathway contributes to progression and worse clinical outcome of hepatocellular carcinoma. (2004) (19)
- Acute intraoperative hemolysis and hemoglobinuria during radiofrequency ablation of hepatocellular carcinoma. (2003) (19)
- Management of Spontaneously Ruptured Hepatocellular Carcinomas in the Radiofrequency Ablation Era (2014) (19)
- Optimal Initial Treatment for Early Hepatocellular Carcinoma in Patients with Preserved Liver Function: Transplantation or Resection? (2007) (18)
- Synchronous resections of primary colorectal tumor and liver metastasis by laparoscopic approach. (2013) (18)
- Clinical significance of serum vascular cell adhesion molecule-1 levels in patients with hepatocellular carcinoma. (2004) (18)
- Modified Anterior Approach for the ALPPS Procedure: How We Do It (2015) (18)
- Therapeutic potential of cardiotrophin 1 in fulminant hepatic failure: dual roles in antiapoptosis and cell repair. (2006) (17)
- Dissecting EASL/AASLD Recommendations With a More Careful Knife: A Comment on "Surgical Misinterpretation" of the BCLC Staging System. (2015) (16)
- Comparison of Survival Outcomes Between Right Posterior Sectionectomy and Right Hepatectomy for Hepatocellular Carcinoma in Cirrhotic Liver: A Single-Centre Experience (2015) (16)
- Suppression of Slit3 induces tumor proliferation and chemoresistance in hepatocellular carcinoma through activation of GSK3β/β-catenin pathway (2018) (16)
- A multicenter phase II study of sorafenib, capecitabine, and oxaliplatin (SECOX) in patients with advanced hepatocellular carcinoma: Final results of Hong Kong-Singapore Hepatocellular Carcinoma Research Collaborative Group study. (2013) (15)
- Intraoperative Iatrogenic Rupture of Hepatocellular Carcinoma (2002) (15)
- p27Kip1 Promotes Migration of Metastatic Hepatocellular Carcinoma Cells (2008) (15)
- Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib (2010) (14)
- Analysis of long‐term survival after hepatectomy for isolated liver metastasis of gastrointestinal stromal tumour (2014) (14)
- Evaluation of patupilone as monotherapy in patients with advanced hepatocellular carcinoma (HCC) (2007) (14)
- Outcomes of central bisectionectomy for hepatocellular carcinoma. (2013) (14)
- Safety and efficacy of radiofrequency ablation for periductal hepatocellular carcinoma with intraductal cooling of the central bile duct. (2008) (14)
- Current treatment strategy for hepatocellular carcinoma. (2007) (13)
- Efficacy and tolerability of single agent sorafenib in poor risk advanced hepatocellular carcinoma patients (2008) (13)
- Primary perivascular epithelioid cell tumour (PEComa) of the liver (2013) (13)
- A phase II trial of MEK inhibitor BAY 86-9766 in combination with sorafenib as first-line systemic treatment for patients with unresectable hepatocellular carcinoma (HCC). (2012) (13)
- Does diabetes mellitus influence the perioperative outcome or long term prognosis after resection of hepatocellular carcinoma (2002) (13)
- The Roles of Lipocalin-2 in Small-for-Size Fatty Liver Graft Injury (2014) (12)
- Emergence of CD26+ Cancer Stem Cells with Metastatic Properties in Colorectal Carcinogenesis (2017) (12)
- Nine-year experience of doxorubicin-eluting beads chemoembolization for hepatocellular carcinoma. (2016) (11)
- Radiofrequency Ablation Combined with Resection Enhances Chance for Curative Treatment of Hepatocellular Carcinoma (2007) (11)
- Brunner's gland adenoma: unusual cause of duodenal haemorrhage and obstruction. (2013) (10)
- Long-term survival after intraluminal brachytherapy for inoperable hilar cholangiocarcinoma: a case report. (2005) (10)
- Re‐resection for metachronous primary hepatocellular carcinoma: is it justified? (2012) (10)
- Survival outcome of re‐resection for recurrent liver metastases of colorectal cancer: a retrospective study (2014) (10)
- Reply to Letter: "Long-term Survival Analysis of Pure Laparoscopic Versus Open Hepatectomy for Hepatocellular Carcinoma in Patients With Cirrhosis: A Single-center Experience". (2015) (9)
- Advanced pancreatic cancer: flourishing novel approaches in the era of biological therapy. (2014) (9)
- Repeated resections of extrahepatic metastases after hepatic resection: an aggressive approach to hepatocellular carcinoma. (2004) (9)
- Phase II study of front-line dovitinib (TKI258) versus sorafenib in patients (Pts) with advanced hepatocellular carcinoma (HCC). (2015) (8)
- 665 A PHASE I/II STUDY OF FORETINIB, AN ORAL MULTIKINASE INHIBITOR TARGETING MET, RON, AXL, TIE-2 AND VEGFR IN ADVANCED HEPATOCELLULAR CARCINOMA (HCC) (2011) (8)
- Current role of laparoscopic surgery for liver malignancies. (2007) (8)
- High-intensity focused ultrasound as a treatment for colorectal liver metastasis in difficult position (2011) (8)
- A phase I study of recombinant human arginase I (rhArgI) for patients with advanced hepatocellular carcinoma (2010) (7)
- Duodenopleural fistula formation after percutaneous radiofrequency ablation for recurrent hepatocellular carcinoma. (2007) (7)
- Radiofrequency ablation for controlling iatrogenic splenic injury (2009) (7)
- Retrospective study of metachronous lung metastases from primary hepatocellular carcinoma (2016) (6)
- Molecular predictors of recurrence prevention with sorafenib as adjuvant therapy in hepatocellular carcinoma: Biomarker study of the STORM phase III trial (2017) (6)
- Overexpression of Pin1 and rho signaling partners correlates with metastatic behavior and poor recurrence-free survival of hepatocellular carcinoma patients (2019) (6)
- Liver Transplantation for Solitary Hepatocellular Carcinoma Less than 3 cm in Diameter in Child A Cirrhosis (2007) (6)
- Gastrointestinal tumors, non-colorectal (2012) (6)
- Induction of long‐term liver allograft survival by delayed immunosuppression is dependent on interleukin‐10 (2007) (6)
- Corrigendum to 'Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study' [Eur J Canc 81 (2017) 17-25]. (2018) (5)
- 1206 Phase I study of Pazopanib (PAZ) in Hepatocellular Carcinoma (HCC): evaluation of clinical activity, Pharmacokinetics (PK), and Dynamic Contrast Enhanced MRI (DCE-MRI) (2009) (5)
- Preliminary efficacy, safety, pharmacokinetics, pharmacodynamics, and quality of life study of pegylated recombinant human arginase 1 in patients with advanced hepatocellular carcinoma. (2014) (5)
- Angiogenesis in Hepatocellular Carcinoma (2000) (4)
- Long-Term Disease-Free Survival After Resection of Hepatocellular Carcinoma: Both Tumor Behavior and Surgeon’s Performance Are Important Determinants (2003) (4)
- Improved anterior hepatic transection for isolated hepatocellular carcinoma in the caudate. (2014) (4)
- LBA17RANDOMISED STUDY OF AXITINIB (AXI) PLUS BEST SUPPORTIVE CARE (BSC) VERSUS PLACEBO (PBO) PLUS BSC IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC) FOLLOWING PRIOR ANTIANGIOGENIC THERAPY (2014) (4)
- Long-Term P rognosis A fter R esection o f H epatocellular Carcinoma A ssociated W ith H epatitis B -Related C irrhosis (2000) (4)
- Efficacy and safety of single-agent sunitinib in treating patients with advanced hepatocelluar carcinoma after sorafenib failure: A prospective, open-label, phase II study. (2011) (4)
- Corrigendum to "Alternatively activated (M2) macrophages promote tumour growth and invasiveness in hepatocellular carcinoma" [J Hepatol 2015;62:607-616]. (2016) (4)
- 2337 Ramucirumab (RAM) as a second-line treatment in patients with advanced hepatocellular carcinoma (HCC) following first-line therapy with sorafenib in the randomized phase III REACH study: Analysis of alpha-fetoprotein (AFP) kinetics during treatment (2015) (4)
- Ramucirumab as Second-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Analysis of Reach Patients by Albumin-Bilirubin (ALBI) Grade (2016) (3)
- Clinical implications of altered energy metabolism in patients with cirrhosis. (2002) (3)
- Significance of viral status on prognosis after resection of hepatitis B virus related hepatocellular carcinoma. (2007) (3)
- Clinicopathologic and prognostic significance of the histologic activity of noncancerous liver tissue in hepatitis B virus-associated hepatocellular carcinoma. (2002) (3)
- 810 Improved Long-Term Survival After Major Resection for Hepatocellular Carcinoma: A Multicenter Analysis Based on a New Definition of Major Hepatectomy (2012) (2)
- O-005Ramucirumab (RAM) as second-Line treatment in patients with advanced hepatocellular carcinoma (HCC) following first-line therapy with sorafenib: comprehensive results from the randomized phase III REACH study (2015) (2)
- The Hong Kong consensus statements on unresectable hepatocellular carcinoma: narrative review and update for 2021 (2021) (2)
- Hepatic Resection for Bilobar Hepatocellular Carcinoma (2015) (2)
- Significance of local and circulating cancer stem cells in human liver cancer (2008) (2)
- Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome (PFO) results from the phase 3 REACH study. (2015) (2)
- Clinical Significance of Angiogenesis in Hepatocellular Carcinoma (2003) (1)
- Prognostic Impact of Diabetes Mellitus on Patients with Hepatocellular Carcinoma (2004) (1)
- An unusual cause of epigastric pain. (2013) (1)
- Efficacy and tolerability of sorafenib in elderly patients with advanced hepatocellular carcinoma. (2010) (1)
- Does hepatitis B seroconversion affect survival outcome in patients with hepatitis B related hepatocellular carcinoma? (2016) (1)
- Preoperative serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: a prospective study (Invited Lecture) (2000) (1)
- The use of single-agent sorafenib in the treatment of patients with advanced hepatocellular carcinoma with underlying Child-Pugh B liver cirrhosis. (2011) (1)
- Title Clinical relevance and therapeutic potential of angiopoietin-likeprotein 4 in hepatocellular carcinoma (2014) (1)
- THE POTENTIAL ROLE OF ALLOGRAFT INFLAMMATORY FACTOR 1 (AIF-1) IN MACROPHAGE ACTIVATION IN SMALL-FOR-SIZE LIVER TRANSPLANTATION (2004) (1)
- Recent advances in management of hepatocellular carcinoma (2013) (1)
- Suppression of hypoxia inducible factor-1 a ( HIF-1 a ) by YC-1 is dependent on murine double minute 2 ( Mdm 2 ) q (2006) (1)
- 1030 TRANS-ARTERIAL CHEMO-EMBOLIZATION (TACE) IS SAFE AND EFFICIENT FOR ELDERLY PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC): RESULTS FROM AN INTERNATIONAL META-DATABASE (2012) (1)
- Maximal host tolerance to large-volume hepatic radiofrequency ablation in a rat model (2004) (1)
- Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2016): Advancing HCC Management Through Multi-Disciplinary Approach 7th Meeting, Hong Kong, July 2016: Abstracts (2016) (1)
- Title Proline-rich tyrosine kinase 2 ( Pyk 2 ) promotes cell motility of hepatocellular carcinoma through induction of epithelial to mesenchymal transition (2011) (0)
- Title Desensitization of T lymphocyte function by CXCR3 ligands in human hepatocellular carcinoma (2015) (0)
- 382 Quantitation of HBV covalently closed circular DNA (HBV CCC DNA) in HCC patients (2004) (0)
- Suppression of inducible factor-1 α (HIF-1 α ) by is dependent on double minute 2 (Mdm2) (2006) (0)
- Title High-intensity focused ultrasound for hepatocellular carcinoma : A single-center experience (2011) (0)
- ALPPS for large hepatocellular carcinoma by the anterior approach (2016) (0)
- An open-label, randomized phase II study comparing first-line treatment with dovitinib (TKI258) versus sorafenib in patients with advanced hepatocellular carcinoma. (2012) (0)
- Recent advances and controversies in surgical management of liver diseases: summary of liver sessions of 7th World Congress of IHPBA 2006. (2007) (0)
- High intensity focused ultrasound therapy: a new treatment on the horizon for hepatocellular carcinoma (2011) (0)
- Treatment strategy of hepatocellular carcinoma located in right posterior section in patients with liver cirrhosis: right hepatectomy vs right posterior sectionectomy- a case matched single centre experience (2016) (0)
- Cancer Therapy : Clinical APhase II Study of theEf fi cacy andSafety of theCombination Therapy of theMEK Inhibitor Refametinib ( BAY 86-9766 ) Plus Sorafenib for Asian Patients with Unresectable Hepatocellular Carcinoma (2014) (0)
- Identification of Local and Circulating Cancer Stem Cells in Human Liver Cancer (2008) (0)
- 59 POSTER Adiponectin as a novel therapy for the suppression of liver cancer growth and metastasis (2006) (0)
- Subject Index Vol. 25, 2007 (2007) (0)
- Title TSC 1 / 2 mutations define a molecular subset of HCC withaggressive behaviour and treatment implication (2017) (0)
- Title Differentiating early and late recurrences after resection of HCC in cirrhotic patients : Implications on surveillance , prevention , and treatment strategies (2009) (0)
- Title Radiofrequency ablation for controlling iatrogenic splenic injury (2010) (0)
- Title Emergence of CD 26 + cancer stem cells with metastaticproperties in colorectal carcinogenesis (2017) (0)
- Title Clinical significance of serum vascular cell adhesion molecule-1 levels in patients with hepatocellular carcinoma (2004) (0)
- [485] ROLE OF HBV GENOTYPES, CORE PROMOTER/PRECORE MUTATIONS AND HBVDNA LEVELS ON HEPATOCARCINOGENESIS (2007) (0)
- Comparison of radiofrequency ablation and hepatic re-resection for intrahepatic recurrent hepatocellular carcinoma (2006) (0)
- INDUCTION OF DONOR-SPECIFIC TRANSPLANTATION TOLERANCE BY ALLOANTIGEN-PRIMED MONOCYTE- DERIVED PROGENITOR CELLS COMBINED WITH LOW- DOSE IMMUNOSUPPRESSION: 1497 (2008) (0)
- Systemic Management of Advanced Hepatocellular Carcinoma Patients: The Role of Multi-Targeted Anti-Angiogenic Inhibitors (2012) (0)
- Resection of hepatocellular carcinoma after combined treatment with transarterial chemoembolization and sorafenib: a case report and literature review (2015) (0)
- Blockade of VEGF/VEGFR pathway enhances chemo-sensitivity in hepatocellular carcinoma (2007) (0)
- Title Management of spontaneously ruptured hepatocellularcarcinomas in the radiofrequency ablation era (2014) (0)
- Title Page / Table of Contents (2016) (0)
- 157 POSTER Combination therapy for liver tumor growth and metastasis by low dose rapamycin and FTY720 (2006) (0)
- The potential role of early-phase graft injury in induction of late-phase chemoresistance after liver transplantation (2010) (0)
- Randomized phase II trial of TACE plus everolimus as first-line therapy in localized unresectable hepatocellular carcinoma (HCC): The TRACER trial. (2012) (0)
- Right atrial thrombosis complicating Hickman catheter placement: A case report and literature review (2000) (0)
- Title Synchronous resections of primary colorectal tumor and livermetastasis by laparoscopic approach (2013) (0)
- Subject Index Vol. 72, Suppl. 1, 2007 (2007) (0)
- Title Tumor cyclooxygenase-2 levels correlate with tumorinvasiveness in human hepatocellular carcinoma (2014) (0)
- Circulating oncometabolite 2-hydroxyglutarate (2HG) as a potential surrogate biomarker in patients with isocitrate dehydrogenase mutant (IDHm) intrahepatic cholangiocarcinoma (ICC). (2013) (0)
- 4632 Management of gallstone cholangitis in the era of laparoscopic cholecystectomy. (2000) (0)
- Title Osteopontin overexpression induced tumor progression and chemoresistance to oxaliplatin through induction of stem-like properties in human colorectal cancer (2015) (0)
- Management o f S pontaneous R upture o f H epatocellular Carcinoma: S ingle-Center E xperience (2001) (0)
- Contents Vol. 25, 2007 (2007) (0)
- Significance of proline rich tyrosine kinase 2 (Pyk2) in epithelial-mesenchymal transition (2007) (0)
- AOSOP3 Combination of bevacizumab and erlotinib in the treatment of patients with advanced hepatocellular carcinoma with sorafenib-refractory disease: Results of a pilot phase II study (2012) (0)
- Upper GI 21 (2009) (0)
- FTY 720 : APromising Agent for Treatment ofMetastatic Hepatocellular Carcinoma (2005) (0)
- Imaging , Diagnosis , Prognosis CirculatingOncometabolite 2-Hydroxyglutarate Is aPotential Surrogate Biomarker in Patients with Isocitrate Dehydrogenase-Mutant Intrahepatic Cholangiocarcinoma (2014) (0)
- Abstract 4389:TSC1/2mutations define a molecular subset of HCC with aggressive behavior and treatment implication (2017) (0)
- Resection of Hepatocellular Carcinoma (2009) (0)
- Title Radiofrequency ablation combined with resection enhanceschance for curative treatment of hepatocellular carcinoma (2007) (0)
- A Framework Is Required to Reduce Publication Bias The Academic Surgeon's View (2010) (0)
- A new prognostic classification scheme with treatment guidelines for Asian patients with hepatocellular carcinoma (HCC): The Hong Kong Combined Liver Cancer (HKCLC) classification. (2011) (0)
- Title Survival Analysis of Re-resection Versus Radiofrequency Ablation for Intrahepatic Recurrence After Hepatectomy for Hepatocellular Carcinoma (2011) (0)
- 391 POSTER The significance of Pyk2 in hepatocellular carcinoma invasiveness (2006) (0)
- Title Inflammatory pseudotumor of the liver in association with a gastrointestinal stromal tumor: A case report (2004) (0)
- Title A garlic derivative , s-allylcysteine ( sac ) , suppresses proliferationand metastasis of hepatocellular carcinoma (2012) (0)
- CONCURRENT SESSIONS: INVITED SPEAKERS (2010) (0)
- Title Genome-wide association study of hepatocellular carcinoma in Southern Chinese patients with chronic hepatitis B virus infection (2011) (0)
- Role of Serum Alpha-Fetoprotein Monitoring in Detection of Recurrent Hepatocellular Carcinoma after Curative Hepatectomy (2003) (0)
- A multi-center phase II trial of bevacizumab (B) pre- and post-transarterial chemoembolization (TACE) treatment for patients with localized unresectable HCC: interim safety report (2010) (0)
- Title A phase 1 dose-escalating study of pegylated recombinant human arginase 1 ( Peg-rhArg 1 ) in patients with advanced hepatocellular carcinoma (2012) (0)
- Title Tuberculosis of pancreas and peripancreatic lymph nodes inimmunocompetent patients : Experience from China (2003) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Ronnie Tung‐ping Poon?
Ronnie Tung‐ping Poon is affiliated with the following schools: